This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in combination with a PD-1 inhibitor or chemotherapy.
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in combination with a PD-1 inhibitor or chemotherapy.
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
-
Carolina BioOncology Institute, Huntersville, North Carolina, United States, 28078
Sarah Cannon Research Institute University of Oklahoma, Oklahoma City, Oklahoma, United States, 73104
SCRI Oncology Partners, Nashville, Tennessee, United States, 37203
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, 77030
Tranquility Research, Webster, Texas, United States, 77598
NEXT Oncology, Fairfax, Virginia, United States, 22031
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Phanes Therapeutics,
2028-08